Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models

Dec 19, 2025Vaccine

Herpes zoster mRNA vaccine produces stronger immune responses and is safely tolerated compared to approved vaccines in animals

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

LVRNA015, a novel VZV mRNA vaccine candidate, produced robust immune responses in mice for over 9 months.

LVRNA015 elicited stronger humoral and cellular immune responses compared to live attenuated VZV.
Mice vaccinated with LVRNA015 had significantly higher levels of neutralizing antibodies and T-cell cytokine production than those given Shingrix®.
The vaccine induced a long-lasting immune memory, with memory T cells detectable 7 months post-vaccination.
Toxicity studies in rats showed no significant changes in body weight or blood markers after LVRNA015 administration.
No hypersensitivity reactions were observed in guinea pigs tested for systemic anaphylaxis.

AI simplified

Herpes zoster, a painful rash that is commonly known as shingles, occurs when the varicella-zoster virus is reactivated from its latent state in neurons. The condition is more frequent among older or immunocompromised individuals. Although the licensed vaccine Shingrix® has demonstrated high efficacy against herpes zoster, its undesired reactogenicity and escalating global demand have necessitated the development of improved or novel VZV vaccines. In the present research, we developed a VZV mRNA vaccine candidate, LVRNA015, that contains sequence-optimized mRNA encoding modified glycoprotein E encapsulated in an ionizable lipid nanoparticle. Our results demonstrated that LVRNA015 exhibited robust humoral and cellular immune responses for over 9 months in BALB/c mice. The magnitude of these responses was significantly higher than that observed with live attenuated VZV. Notably, mice vaccinated with LVRNA015 exhibited significantly higher neutralizing antibody levels and antigen-specific T-cell cytokine production in comparison with those receiving Shingrix®. Additionally, LVRNA015 induced a long-lasting immunological memory response, as evidenced by detection of memory T cells at 7 months after the final immunization. To evaluate vaccine safety, acute and repeat-dose toxicity studies were performed in rats; no significant alterations in body weight or in hematological and biochemical markers were observed following LVRNA015 administration. Active systemic anaphylaxis tests in guinea pigs showed no hypersensitivity in LVRNA015-treated animals. These findings support the further advancement of LVRNA015 to clinical studies as a promising shingles vaccine.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief